Table 3: Cross resistance levels for the mutants obtained.

From: Development and characterisation of highly antibiotic resistant Bartonella bacilliformis mutants

Table 3: Cross resistance levels for the mutants obtained.
 MIC 1/ (fold)2
Azithromycin (AZM)3Chloramphenicol (CHL)3Ciprofloxacin (CIP)3Rifampicin (RIF)3
Ab457.18Azm-3557.19 Azm-3557.20 Azm-3557.18Chl-4057.19Chl-3557.20Chl-4057.18Cip-3557.19Cip-3557.20Cip-3557.18Rif-3557.19Rif-3557.20Rif-35
AZM<0.016
(<0.08)
<0.016 (ND)<0.016
(<0.25)
<0.016
(<0.08)
0.064
(>4.00)
0.094 (1.47)<0.016
(<0.08)
<0.016
(ND)
0.094 (1.47)
CHL2 (5.26)0.5 (4.00)0.38 ((1.52)0.125 (0.33)0.5 (4.00)0.25 (1.00)0.75 ((1.97)0.75 (6.00)1 (4.00)
CIP0.75 (1.50)0.125 (0.33)1 (2.63)0.38 ((0.76)0.125 (0.33)0.25 ((0.66)0.38 ((0.76)2 (5.26)0.047 (0.12)
RIF<0.016
(ND)
<0.016
(<1.00)
<0.016
(ND)
<0.016
(ND)
<0.016
(<1.00)
<0.016
(ND)
<0.016
(ND)
<0.016
(<1.00)
<0.016
(ND)
  1. The cases in which the MIC of the mutant decreased with respect to the parental isolate are highlighted in underlined font while those in which the MIC increased, (expressed in mg/L) are shown in bold.
  2. ND: not-determined.
  3. 1Minimal Inhibitory Concentration in mg/L.
  4. 2Fold: MIC fold increase/decrease compared to parental isolate. When the quotient ranks between 0.5 and 2 no effect was considered. Values ≥ 2 represent a co-selection of resistance, while values < 0.5 indicate that the mutant strain increased its susceptibility levels to the antimicrobial agent analysed.
  5. 3Antibiotic used in the selection of resistant mutants.
  6. 4Antibiotic tested.